Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
about
Kinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival.Defining human diabetic nephropathy on the molecular level: integration of transcriptomic profiles with biological knowledge.New experimental and theoretical investigations of hematopoietic stem cells and chronic myeloid leukemia.Absolute quantification of BCR-ABL1 fusion transcripts in pediatric chronic myeloid leukemia.Platelet-derived growth factor receptors and ligands are up-regulated in paediatric fibromatoses
P2860
Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Monitoring minimal residual di ...... guide to clinical management.
@ast
Monitoring minimal residual di ...... guide to clinical management.
@en
type
label
Monitoring minimal residual di ...... guide to clinical management.
@ast
Monitoring minimal residual di ...... guide to clinical management.
@en
prefLabel
Monitoring minimal residual di ...... guide to clinical management.
@ast
Monitoring minimal residual di ...... guide to clinical management.
@en
P50
P356
P1476
Monitoring minimal residual di ...... guide to clinical management.
@en
P2093
Daniela Cilloni
P304
P356
10.1002/HON.792
P577
2006-12-01T00:00:00Z